Kretzler to be Honored with Young Investigator Award at Friday Plenary Session

Matthias Kretzler

/kidneynews/1_5/34a/graphic/34af1.jpg

The American Society of Nephrology is delighted to present this year’s Young Investigator Award to Matthias Kretzler, MD, whose work to define the molecular mechanisms of kidney disease is helping to identify better ways to predict and treat it.

Initiated in 1985, the Young Investigator Award each year recognizes an individual with an outstanding record of achievement and creativity in basic or patient-oriented research related to the functions and diseases of the kidney. The award is co-sponsored by the American Heart Association’s Council on the Kidney and is limited to individuals who are younger than 41 on the first day of the ASN meeting at which the award is presented, or who are less than eight years from the start of their first faculty or staff research scientist position beyond postdoctoral training.

Dr. Kretzler is an associate professor of internal medicine in the division of nephrology at the University of Michigan, Ann Arbor, where he teaches medical students, internal medicine residents, and nephrology fellows.

In addition to his teaching responsibilities, he is involved in a number of research initiatives at the state, national, and international levels. His research on chronic kidney disease addresses mechanisms for diabetic nephropathy, nephrotic syndrome, lupus nephritis, and IgA nephritis.

Since arriving at the University of Michigan in 2005, Dr. Kretzler has established the Personalized Molecular Nephrology Laboratory and the Michigan Renal Biobank.

The laboratory uses modern molecular biology tools to better understand disease mechanisms activated in human renal biopsies. Dr. Kretzler and his team use these tools for molecular diagnosis of kidney and transplant failure in international multicenter studies.

The Michigan Renal Biobank is a registry of medical histories, biopsy tissues, and specimens from patients with nephrotic syndrome and focal segmental glomerulosclerosis (FSGS). The biobank allows for development of a system of markers to subdivide different forms of FSGS, providing finer details as to prognosis, responsiveness to various drugs, and why some patients fail to respond to treatment.

At the national level, Dr. Kretzler initiated the Nephcure Biobank to establish prospective cohorts of patients with nephrotic syndrome for molecular phenotyping. In the international realm, he continues to integrate regional and national resources with the European Renal cDNA Bank, which he founded.

Dr. Kretzler serves on the advisory board of the European Kidney Research Association and on the editorial boards of the Journal of the American Society of Nephrology, the Journal of Nephrology, Clinical Nephrology, and Nephrology, Dialysis, and Transplantation.